The safety of treatment with ERBB2-specific autologous CAR-T cells was initially demonstrated in a phase I/II clinical trial in sarcoma patients at Baylor College of Medicine, Houston, Texas, USA [38]. This evidence concerns the gene ERBB2 and sarcoma.